Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

In standard-risk acute promyelocytic leukemia, recent results have shown that all-trans retinoic acid plus arsenic trioxide combinations are at least as effective as classical all-trans retinoic acid plus anthracycline-based chemotherapy while being less myelosuppressive. However, the role of frontl...

Full description

Bibliographic Details
Main Authors: Lionel Adès, Xavier Thomas, Agnes Guerci Bresler, Emmanuel Raffoux, Olivier Spertini, Norbert Vey, Tony Marchand, Christian Récher, Arnaud Pigneux, Stephane Girault, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean Francois Lambert, Patrice Chevallier, Stephane de Botton, Julie Lejeune, Hervé Dombret, Sylvie Chevret, Pierre Fenaux
Format: Article
Language:English
Published: Ferrata Storti Foundation 2018-12-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/8699

Internet

https://haematologica.org/article/view/8699

Similar Items